Quotient (NASDAQ:QTNT) released its earnings results on Monday. The company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.01), Fidelity Earnings reports. Quotient had a negative net margin of 333.37% and a negative return on equity of 5,998.14%. The business had revenue of $7.85 million for the quarter, compared to the consensus estimate of $6.80 million.
Shares of QTNT stock traded up $0.06 on Thursday, hitting $7.75. 67,373 shares of the company’s stock traded hands, compared to its average volume of 301,492. The company has a debt-to-equity ratio of 72.27, a quick ratio of 4.42 and a current ratio of 5.17. Quotient has a one year low of $5.73 and a one year high of $11.30. The company’s fifty day simple moving average is $7.96 and its 200 day simple moving average is $9.06. The stock has a market capitalization of $516.90 million, a price-to-earnings ratio of -4.01 and a beta of 0.99.
In related news, insider Roland Boyd sold 21,100 shares of the stock in a transaction on Monday, August 19th. The shares were sold at an average price of $10.95, for a total transaction of $231,045.00. Following the transaction, the insider now owns 62,508 shares of the company’s stock, valued at approximately $684,462.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 14.20% of the stock is currently owned by company insiders.
QTNT has been the topic of several recent research reports. BidaskClub raised shares of Quotient from a “strong sell” rating to a “sell” rating in a report on Friday, October 18th. ValuEngine raised shares of Quotient from a “sell” rating to a “hold” rating in a report on Saturday, October 19th. Finally, Zacks Investment Research raised shares of Quotient from a “hold” rating to a “strong-buy” rating and set a $9.75 target price on the stock in a report on Thursday, October 24th.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Featured Story: Certificate of Deposit (CD) For Risk Adverse Investors?
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.